TABLE 2

Impact of coadministered drugs on DAA exposure (AUC)

Data are given in percentages.

Drug ClassSMPSOFLDV/SOFDCVOBV/PTV/DSV/rEBR/GZRSOF/VELSOF/VEL/VOXGLE/PIB
LDVOBVPTVDSV/rGZREBRVELVOXGLEPIB
Immunosuppressants
 Cyclosporine↑468a↑353b↑40d↑72↑ 30↑1421c,d↑98↑103b↑839b↑408c,d↑93c
 Everolimus↑26
 Mycophenolate mofetil↓26
 Sirolimus↑19
 Tacrolimus↑90a↑13↓34
Statins and lipid-lowering agents
 Atorvastatin↑26
 Gemfibrozil↑38↑1025
 Lovastatin
 Pitavastatin
 Pravastatin↑24
 Rosuvastatin↑52
 Simvastatin
Cardiovascular
 Amiodarone
 Amlodipine↓22
 Digoxin
Antifungals
 Ketoconazole↑200↑98↑42↑57↑202↑80↑71
 Voriconazole↑84
Acid-reducing agents
 Famotidine
 Omeprazole↓4–42c↓26–55c↓29–51c
 Pantoprazole
Antibacterial agents
 Erythromycin↑647
 Rifampin↓48↓72↓59↓79↔,f ↑921,g ↑735hg,h↑46 SD, ↓82 MD↑691 SD, ↓73 MD↑755 SD, ↓88 MD↔ SD, ↓87 MD
CNS agents
 Buprenorphine/naloxone↓14↑22
 Carbamazepine↓48↓31↓70↓70↓87↓66↓51
 Escitalopram↓25
 Methadone↑30↑20
Other
 OC (norgestimate, norgestrel, EE, or levonorgestrel)e↓34e↓52e↓29e
  • CNS, central nervous system; DCV, daclatasvir; DSV, dasabuvir; EBR, elbasvir; EE, ethinyl estradiol; GLE, glecaprevir; GZR, grazoprevir; LDV, ledipasvir; OBV, ombitasvir; OC, oral contraceptive; PIB, pibrentasvir; PTV, paritaprevir; SD, single dose; /r, ritonavir; SMP, simeprevir; SOF, sofosbuvir; VEL, velpatasvir; VOX, voxilaprevir. ↑: increase in exposure; ↓: decrease in exposure; ↔: no change; —: data not available.

  • a Individualized dosing.

  • b 600 mg cyclosporine.

  • c Depends on staggering of acid-reducing agent.

  • d 400 mg cyclosporine.

  • e EE/norgestimate.

  • f 600 mg rifampin orally daily.

  • g 600 mg rifampin intravenously SD.

  • h 600 mg rifampin orally SD.